60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a report released on Saturday morning,Weiss Ratings reports.

Separately, HC Wainwright reiterated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 28th.

60 Degrees Pharmaceuticals Stock Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $2.42 on Friday. 60 Degrees Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $35.99. The company has a market capitalization of $3.56 million, a P/E ratio of -0.24 and a beta of 3.02. The company’s fifty day moving average is $2.33 and its two-hundred day moving average is $3.89.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.